Is Avadel Pharmaceuticals Stock a Good Investment?
Avadel Pharmaceuticals Investment Advice | AVDL |
- Examine Avadel Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Avadel Pharmaceuticals' leadership team and their track record. Good management can help Avadel Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Avadel Pharmaceuticals' business and its evolving consumer preferences.
- Compare Avadel Pharmaceuticals' performance and market position to its competitors. Analyze how Avadel Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Avadel Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Avadel Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Avadel Pharmaceuticals PLC stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Avadel Pharmaceuticals PLC is a good investment.
Sell | Buy |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Avadel Pharmaceuticals Stock
Researching Avadel Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 80.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.07. Avadel Pharmaceuticals recorded a loss per share of 1.09. The entity had not issued any dividends in recent years.
To determine if Avadel Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Avadel Pharmaceuticals' research are outlined below:
| Avadel Pharmaceuticals generated a negative expected return over the last 90 days | |
| Avadel Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 27.96 M. Net Loss for the year was (160.28 M) with profit before overhead, payroll, taxes, and interest of 16.59 M. | |
| Avadel Pharmaceuticals PLC currently holds about 104.12 M in cash with (128.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.74. | |
| Avadel Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 80.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year ... |
Avadel Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Avadel Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Avadel Pharmaceuticals PLC. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Avadel Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Avadel Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Avadel Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-08 | 2024-06-30 | -0.16 | -0.14 | 0.02 | 12 | ||
1999-02-23 | 1998-12-31 | -0.1 | -0.12 | -0.02 | 20 | ||
2024-11-06 | 2024-09-30 | -0.05 | -0.0273 | 0.0227 | 45 | ||
2024-02-29 | 2023-12-31 | -0.26 | -0.29 | -0.03 | 11 | ||
2019-11-12 | 2019-09-30 | -0.27 | -0.24 | 0.03 | 11 | ||
1997-03-26 | 1996-12-31 | -0.18 | -0.15 | 0.03 | 16 | ||
2023-11-08 | 2023-09-30 | -0.37 | -0.41 | -0.04 | 10 | ||
2015-05-15 | 2015-03-31 | 0.31 | 0.27 | -0.04 | 12 |
Avadel Pharmaceuticals Target Price Consensus
Avadel target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Avadel Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 10 | Strong Buy |
Most Avadel analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Avadel stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Avadel Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAvadel Pharmaceuticals Target Price Projection
Avadel Pharmaceuticals' current and average target prices are 8.10 and 24.70, respectively. The current price of Avadel Pharmaceuticals is the price at which Avadel Pharmaceuticals PLC is currently trading. On the other hand, Avadel Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Avadel Pharmaceuticals Market Quote on 25th of February 2025
Target Price
Analyst Consensus On Avadel Pharmaceuticals Target Price
Avadel Pharmaceuticals Analyst Ratings
Avadel Pharmaceuticals' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Avadel Pharmaceuticals stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Avadel Pharmaceuticals' financials, market performance, and future outlook by experienced professionals. Avadel Pharmaceuticals' historical ratings below, therefore, can serve as a valuable tool for investors.Know Avadel Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Avadel Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Avadel Pharmaceuticals PLC backward and forwards among themselves. Avadel Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Avadel Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goldman Sachs Group Inc | 2024-12-31 | 2.1 M | Tri Locum Partners Lp | 2024-12-31 | 1.9 M | State Street Corp | 2024-12-31 | 1.7 M | Ubs Group Ag | 2024-12-31 | 1.6 M | Tang Capital Management Llc | 2024-12-31 | 1.5 M | Millennium Management Llc | 2024-12-31 | 1.2 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.2 M | Geode Capital Management, Llc | 2024-12-31 | 1.2 M | Checkpoint Capital Lp | 2024-12-31 | 1 M | Hhg Plc | 2024-12-31 | 14.1 M | Gendell Jeffrey L | 2024-12-31 | 6.3 M |
Avadel Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.27 B.Market Cap |
|
Avadel Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.25) | (1.18) | |
| Return On Capital Employed | (1.24) | (1.18) | |
| Return On Assets | (1.12) | (1.06) | |
| Return On Equity | (2.10) | (2.21) |
Determining Avadel Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Avadel Pharmaceuticals is a good buy. For example, gross profit margin measures Avadel Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Avadel Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Avadel Pharmaceuticals' management efficiency
Avadel Pharmaceuticals has return on total asset (ROA) of (0.3445) % which means that it has lost $0.3445 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9952) %, meaning that it created substantial loss on money invested by shareholders. Avadel Pharmaceuticals' management efficiency ratios could be used to measure how well Avadel Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to -1.18 this year. Return On Capital Employed is expected to rise to -1.18 this year. At this time, Avadel Pharmaceuticals' Non Current Assets Total are quite stable compared to the past year. Intangibles To Total Assets is expected to rise to 0.21 this year, although the value of Total Assets will most likely fall to about 134.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.26 | 1.77 | |
| Tangible Book Value Per Share | 1.02 | 1.28 | |
| Enterprise Value Over EBITDA | (6.86) | (7.20) | |
| Price Book Value Ratio | 14.84 | 15.58 | |
| Enterprise Value Multiple | (6.86) | (7.20) | |
| Price Fair Value | 14.84 | 15.58 | |
| Enterprise Value | 388.4 M | 201.8 M |
Management at Avadel Pharmaceuticals focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Beta 1.632 |
Basic technical analysis of Avadel Stock
As of the 25th of February, Avadel Pharmaceuticals shows the risk adjusted performance of (0.04), and Mean Deviation of 2.57. Avadel Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Avadel Pharmaceuticals standard deviation, as well as the relationship between the maximum drawdown and kurtosis to decide if Avadel Pharmaceuticals is priced correctly, providing market reflects its regular price of 8.1 per share. Given that Avadel Pharmaceuticals has information ratio of (0.07), we suggest you to validate Avadel Pharmaceuticals PLC's prevailing market performance to make sure the company can sustain itself at a future point.Avadel Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Avadel Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Avadel Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Avadel Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Avadel Pharmaceuticals' Outstanding Corporate Bonds
Avadel Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Avadel Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Avadel bonds can be classified according to their maturity, which is the date when Avadel Pharmaceuticals PLC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand Avadel Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Avadel Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.25) | |||
| Mean Deviation | 2.57 | |||
| Coefficient Of Variation | (1,507) | |||
| Standard Deviation | 4.63 | |||
| Variance | 21.47 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.31) | |||
| Total Risk Alpha | (0.29) | |||
| Treynor Ratio | (0.26) | |||
| Maximum Drawdown | 34.56 | |||
| Value At Risk | (4.23) | |||
| Potential Upside | 4.79 | |||
| Skewness | (2.70) | |||
| Kurtosis | 15.67 |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.25) | |||
| Mean Deviation | 2.57 | |||
| Coefficient Of Variation | (1,507) | |||
| Standard Deviation | 4.63 | |||
| Variance | 21.47 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.31) | |||
| Total Risk Alpha | (0.29) | |||
| Treynor Ratio | (0.26) | |||
| Maximum Drawdown | 34.56 | |||
| Value At Risk | (4.23) | |||
| Potential Upside | 4.79 | |||
| Skewness | (2.70) | |||
| Kurtosis | 15.67 |
Consider Avadel Pharmaceuticals' intraday indicators
Avadel Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Avadel Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 88406.05 | |||
| Daily Balance Of Power | (0.33) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 8.18 | |||
| Day Typical Price | 8.15 | |||
| Price Action Indicator | (0.15) | |||
| Period Momentum Indicator | (0.14) | |||
| Relative Strength Index | 56.54 |
Avadel Pharmaceuticals Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 28th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 8th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Avadel Stock media impact
Far too much social signal, news, headlines, and media speculation about Avadel Pharmaceuticals that are available to investors today. That information is available publicly through Avadel media outlets and privately through word of mouth or via Avadel internal channels. However, regardless of the origin, that massive amount of Avadel data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Avadel Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Avadel Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Avadel Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Avadel Pharmaceuticals alpha.
Avadel Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Avadel Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Avadel Pharmaceuticals Historical Investor Sentiment
Investor biases related to Avadel Pharmaceuticals' public news can be used to forecast risks associated with an investment in Avadel. The trend in average sentiment can be used to explain how an investor holding Avadel can time the market purely based on public headlines and social activities around Avadel Pharmaceuticals PLC. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Avadel Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Avadel Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Avadel Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Avadel Pharmaceuticals.
Avadel Pharmaceuticals Corporate Management
| Gregory Davis | VP Development | Profile | |
| Richard Kim | Chief Officer | Profile | |
| Christian PharmD | Chief Affairs | Profile | |
| Steven Sullivan | VP Operations | Profile | |
| Jason Vaughn | Senior Operations | Profile | |
| Jennifer PharmD | Senior Affairs | Profile |
Already Invested in Avadel Pharmaceuticals PLC?
The danger of trading Avadel Pharmaceuticals PLC is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Avadel Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Avadel Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Avadel Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Avadel Pharmaceuticals is a strong investment it is important to analyze Avadel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Avadel Pharmaceuticals' future performance. For an informed investment choice regarding Avadel Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.09) | Revenue Per Share | Quarterly Revenue Growth 26.743 | Return On Assets | Return On Equity |
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Avadel Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.